Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 14

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 14
---
, which in turn attracted potential business partners to
approach NewGenIvf to negotiate cooperations and referrals. Over the years, NewGenIvf sends representatives to medical expos mostly
held in the PRC to approach potential business partners and establish new partnerships by entering into agency agreements with each
agent. NewGenIvf has become a significant partner with agents and sub-agents throughout China and India. Normally, each agency
agreement has a maximum term of one year, which is renewable upon mutual agreement. Agents typically market and promote
NewGenIvf’s services by word-to-mouth referrals and other measures and NewGenIvf pays the agents commission at a range of 10%
to 25% of the treatment fees upon the completion of client’s treatment. Normally, agents provide potential clients’
contact information to the sales team of NewGenIvf, who then approach potential clients and provide consultation on services. With
its partnerships in various countries, NewGenIvf believes it is able to better benefit from the growing market opportunities.

<div align='center'>3</div>

Exclusively Owned and Licensed Technology for Family Planning and Access to Mature Fertility Technologies NewGenIvf believes that its licenses and/or access to mature technologies contribute to its ability to identify and tailor ARS services to individual patient’s needs. These technologies include:

| ● | Preimplantation Genetic Screening (“PGS”): PGS is used in parallel with an IVF treatment cycle. PGS is the practice of determining the presence of aneuploidy (either too many or too few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization by ensuring the transfer of euploid embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved clinical outcomes for NewGenIvf by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%. |

| ● | Next-Generation Sequencing (“NGS”): NGS is a high-throughput technology for determining the sequence of deoxyribonucleic acid (“DNA”) or ribonucleic acid (“RNA”) to study genetic variation associated with diseases or other biological phenomena. NGS determines the sequence of a sample all at once by using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample one section at a time. Sequencing thousands of gene fragments simultaneously with NGS reduces time and cost associated with sequencing and increases the coverage quality and data output